Cagrilintide semaglutide dosage is not FDA-approved for human use; learn the investigational CagriSema trial doses, titration steps, and safety facts.
There is no FDA-approved cagrilintide semaglutide dosage for human use in the United States. Cagrilintide and semaglutide are combined as an investigational treatment called CagriSema, which has been studied in clinical trials at a fixed weekly dose of cagrilintide 2.4 mg plus semaglutide 2.4 mg after a stepwise titration. The combination is not commercially available, and no dosing schedule should be used outside a supervised clinical trial.
Many people search for a cagrilintide semaglutide dosage chart because they have heard about the weight-loss results from early studies. This article explains what the research protocols actually used, why those numbers are not a prescription, and what safety issues matter.
What Is the Cagrilintide and Semaglutide Combination?
Cagrilintide is a long-acting amylin analog. Semaglutide is a GLP-1 receptor agonist. Both hormones affect appetite and digestion, but they work through different pathways.
Researchers combine them to target two satiety systems at once. The investigational fixed-dose product is called CagriSema. Many researchers also look into cagrilintide and semaglutide as a dual-hormone approach for obesity and type 2 diabetes.
CagriSema is not approved by the FDA, the EMA, or any other major regulator as of this writing. It remains in phase 3 clinical trials.
Cagrilintide Semaglutide Dosage Chart From Clinical Trials
The table below summarizes dosing used in published CagriSema studies. These numbers are for research only. They are not a recommendation for any individual.
| Study | Cagrilintide Dose | Semaglutide Dose | Frequency | Notes |
|---|---|---|---|---|
| Phase 2 trial (2021) | 2.4 mg | 2.4 mg | Once weekly | Doses escalated over about 20 weeks |
| REDEFINE-1 (phase 3) | 2.4 mg | 2.4 mg | Once weekly | Fixed-dose combination; titration every 4 weeks |
| REDEFINE-2 (phase 3) | 2.4 mg | 2.4 mg | Once weekly | Same target dose in adults with type 2 diabetes |
| Dose-finding studies | 0.16–2.4 mg | 0.25–2.4 mg | Once weekly | Sequential escalation to limit side effects |
A typical cagrilintide and semaglutide dosing chart from the phase 2 trial looked like this: 0.16 mg cagrilintide plus 0.25 mg semaglutide for 4 weeks, then 0.3 mg plus 0.5 mg for 4 weeks, then 0.6 mg plus 1.0 mg, then 1.2 mg plus 1.7 mg, and finally 2.4 mg plus 2.4 mg.
Do not copy this schedule. It is a study protocol, not medical advice.
How Titration Works in CagriSema Studies
Titration means starting low and increasing slowly. This approach helps the body adjust and reduces nausea, vomiting, and other gastrointestinal effects.
In CagriSema trials, participants usually stayed at each dose level for four weeks. If side effects were too strong, the next increase could be delayed or the dose reduced.
Every trial participant received the drug under medical supervision. Researchers monitored vital signs, lab work, and symptoms throughout the study.
Why There Is No At-Home Cagrilintide Semaglutide Dosage
CagriSema is not for sale. No pharmacy can legally fill a prescription for it in the United States. That means any online cagrilintide dosage sold as a research chemical is unregulated and unapproved.
Compounded semaglutide products are sometimes sold as 5 mg/mL, and a semaglutide 5mg/ml dosage chart exists for those formulations. However, that chart does not apply to CagriSema. The combination adds a second active drug with its own titration needs.
Online discussions like tirzepatide vs semaglutide dosage reddit often mix up approved and investigational products. Reddit threads are not a reliable source for dosing. Similarly, an aod 9604 dosage protocol follows completely different rules because AOD-9604 is a different peptide with different research status.
The safest conclusion is simple: Cagrilintide semaglutide dosage is not something you can determine at home.
Safety and Side Effects of Cagrilintide Plus Semaglutide
In clinical trials, the most common side effects were gastrointestinal. They included nausea, vomiting, diarrhea, and constipation. Most were mild to moderate and temporary.
More serious risks seen with GLP-1 medications and amylin analogs include pancreatitis, gallbladder disease, and kidney problems. These events are rare but require medical attention.
Cagrilintide and semaglutide can also cause low blood sugar when used with insulin or sulfonylureas. Anyone with a history of pancreatitis, severe gastrointestinal disease, or certain thyroid conditions should not use these drugs without specialist guidance.
Always consult a healthcare professional before starting, stopping, or changing any weight-management medication.
Approved Alternatives to Cagrilintide Semaglutide
If you are looking for an evidence-based option today, several medications are FDA-approved. They include semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro).
Each approved product has its own dosing schedule. A doctor can help you choose based on your health history and goals. CagriSema may become available in the future, but it is not an option now.
Frequently Asked Questions
Is there an FDA-approved cagrilintide semaglutide dosage?
No. Cagrilintide plus semaglutide (CagriSema) is an investigational combination and has not been approved by the FDA for any use. No standard cagrilintide semaglutide dosage exists outside clinical trials.
What dose of cagrilintide and semaglutide was studied in trials?
Phase 3 CagriSema trials used a fixed weekly dose of cagrilintide 2.4 mg plus semaglutide 2.4 mg. Participants reached that dose through a stepwise titration that started much lower. These doses are research protocols, not prescribing recommendations.
Can I use a cagrilintide semaglutide dosage chart to dose myself?
No. CagriSema is not commercially available, and self-dosing with research chemicals is dangerous. If you are interested in weight-loss medication, talk to a healthcare professional about FDA-approved options like semaglutide or tirzepatide.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.